See more : Ameren Illinois Company (AILLN) Income Statement Analysis – Financial Results
Complete financial analysis of Benitec Biopharma Inc. (BNTC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Benitec Biopharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- E3 Lithium Limited (EEMMF) Income Statement Analysis – Financial Results
- Banco Davivienda S.A. (PFDAVVNDA.CL) Income Statement Analysis – Financial Results
- Aareal Bank AG (AAALY) Income Statement Analysis – Financial Results
- Jones Soda Co. (JSDA.CN) Income Statement Analysis – Financial Results
- Helios Energy Limited (HLEGF) Income Statement Analysis – Financial Results
Benitec Biopharma Inc. (BNTC)
About Benitec Biopharma Inc.
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 216.00K | 75.00K | 73.00K | 59.00K | 97.00K | 11.32M | 455.45K | 450.31K | 346.51K | 829.13K | 1.02M | 545.73K |
| Cost of Revenue | 108.00K | 381.00K | 9.00K | 123.00K | 268.07K | 426.51K | 331.30K | 209.02K | 103.80K | 30.68K | 37.66K | 176.13K |
| Gross Profit | 108.00K | -306.00K | 64.00K | -64.00K | -171.07K | 10.89M | 124.15K | 241.29K | 242.70K | 798.45K | 980.10K | 369.60K |
| Gross Profit Ratio | 50.00% | -408.00% | 87.67% | -108.47% | -176.36% | 96.23% | 27.26% | 53.58% | 70.04% | 96.30% | 96.30% | 67.73% |
| Research & Development | 15.61M | 12.77M | 11.27M | 7.02M | 3.00M | 2.17M | 5.06M | 5.32M | 9.92M | 4.78M | 5.86M | 3.43M |
| General & Administrative | 6.71M | 6.38M | 6.65M | 6.51M | 5.57M | 6.66M | 6.41M | 6.99M | 8.96M | 6.17M | 7.67M | 4.39M |
| Selling & Marketing | 277.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.99M | 6.38M | 6.65M | 6.51M | 5.57M | 6.66M | 6.41M | 6.99M | 8.96M | 6.17M | 7.67M | 4.39M |
| Other Expenses | -216.00K | -30.00K | -79.00K | 37.00K | -5.00K | 154.77K | 734.59 | -7.91M | -2.68M | -2.14M | -2.18M | -708.18K |
| Operating Expenses | 22.38M | 19.16M | 17.92M | 13.53M | 8.56M | 8.99M | 8.68M | 4.40M | 16.20M | 8.80M | 11.35M | 7.11M |
| Cost & Expenses | 22.49M | 19.16M | 17.93M | 13.66M | 8.38M | 9.41M | 9.01M | 4.61M | 16.31M | 8.84M | 11.38M | 7.28M |
| Interest Income | 0.00 | 49.55K | 46.35K | 0.00 | 62.00K | 119.06K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 904.00K | 33.00K | 32.00K | 6.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 0.00 | 381.00K | 392.00K | 424.00K | 374.00K | 154.77K | 142.51K | 166.75K | 11.54M | 74.40K | 4.50M | 1.52M |
| EBITDA | -22.49M | -18.70M | -17.85M | -13.60M | -7.91M | 2.74M | -8.59M | -4.19M | -13.42M | -7.93M | -9.90M | -6.64M |
| EBITDA Ratio | -10,412.04% | -24,973.33% | -24,565.75% | -22,506.78% | -8,059.79% | 19.07% | -1,846.62% | -840.79% | -3,872.42% | -857.54% | -972.53% | -1,215.89% |
| Operating Income | -22.49M | -19.08M | -17.85M | -13.60M | -8.28M | 2.00M | -8.55M | -15.92M | -24.96M | -13.33M | -14.40M | -8.16M |
| Operating Income Ratio | -10,412.04% | -25,441.33% | -24,457.53% | -23,044.07% | -8,537.11% | 17.70% | -1,877.75% | -3,536.22% | -7,204.20% | -1,607.59% | -1,414.88% | -1,494.87% |
| Total Other Income/Expenses | 120.00K | -481.00K | -354.00K | -286.00K | 7.00K | 606.03K | 179.24K | 11.55M | 6.46M | 4.50M | 3.56M | 1.32M |
| Income Before Tax | -22.37M | -19.56M | -18.21M | -13.88M | -8.27M | 2.87M | -8.55M | -4.37M | -18.50M | -8.83M | -10.84M | -6.84M |
| Income Before Tax Ratio | -10,356.48% | -26,082.67% | -24,942.47% | -23,528.81% | -8,529.90% | 25.34% | -1,877.42% | -970.99% | -5,340.09% | -1,064.66% | -1,064.66% | -1,253.01% |
| Income Tax Expense | -619.00K | 3.00K | 354.00K | -101.00K | 27.00K | -864.22K | 1.47K | 209.79K | -9.00M | 821.46K | -4.03M | -414.32K |
| Net Income | -21.75M | -19.56M | -18.56M | -13.78M | -8.30M | 2.87M | -8.55M | -4.37M | -18.50M | -8.83M | -10.84M | -6.42M |
| Net Income Ratio | -10,069.91% | -26,082.67% | -25,427.40% | -23,357.63% | -8,557.73% | 25.34% | -1,877.42% | -970.99% | -5,340.09% | -1,064.66% | -1,064.66% | -1,177.09% |
| EPS | -5.36 | -14.12 | -38.62 | -54.54 | -138.19 | 56.89 | -207.21 | -127.11 | -663.12 | -389.77 | -611.08 | -1.45K |
| EPS Diluted | -5.36 | -14.12 | -38.62 | -54.54 | -138.19 | 56.89 | -207.21 | -127.11 | -663.12 | -389.77 | -611.08 | -1.45K |
| Weighted Avg Shares Out | 4.06M | 1.39M | 480.69K | 252.67K | 60.07K | 50.40K | 41.27K | 34.40K | 27.90K | 22.65K | 17.73K | 4.43K |
| Weighted Avg Shares Out (Dil) | 4.06M | 1.39M | 480.69K | 252.67K | 60.07K | 50.40K | 41.27K | 34.40K | 27.90K | 22.65K | 17.73K | 4.43K |
Benitec Biopharma to Participate in Upcoming Investor Conferences in December
HAYWARD, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today...
Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update
-Positive 270-day Interim Clinical Study Data for the First Subject and Positive 180-day Interim Clinical Study Data for the Second Subject Treated with the Low-Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in October as a Late-Breaking...
Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference
HAYWARD, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today...
Benitec Biopharma: OPMD Program Continues To Advance With Catalysts
Benitec Biopharma Inc.'s BB-301 showed positive interim results in treating OPMD, allowing for higher dosing in 2025 and a potential late-stage trial in 2026. BB-301 demonstrated significant improvements in swallowing function and reduced pharyngeal residue, with no serious adverse events...
Benitec Biopharma Announces Updated Investor Webcast Information
-Management plans to host an investor webcast on October 14 th at 8:30 am EDT to provide an update for the BB-301 Phase 1b/2a Clinical Study, details below-
Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society
-Subject 1 and Subject 2 experienced durable, clinically meaningful improvements in swallowing at 9-months and 6-months post-BB-301 treatment, respectively, with Subject 2 achieving a Sydney Swallow Questionnaire Score Representative of Clinically Normal Swallowing-
Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update
-Positive 90-day and 180-day Interim Clinical Trial Data for the First Oculopharyngeal Muscular Dystrophy (OPMD) Subject Dosed with the Low-Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in April and July-
Benitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle Society
HAYWARD, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today...
Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phase 1b/2a Study
-The post-dose average values for Total Pharyngeal Residue (i.e., the amount of solid food or liquid material remaining in the pharynx after the first swallow) remained meaningfully reduced at the 180-day post-dose assessment following the administration of the low dose...
Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update
-Positive Interim Clinical Trial Data for the First Oculopharyngeal Muscular Dystrophy (OPMD) Subject Dosed with BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in April-
Source: https://incomestatements.info
Category: Stock Reports